Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Argenica Therapeutics Ltd ( (AU:AGN) ).
Argenica Therapeutics has announced significant findings from a preclinical study indicating that their neuroprotective candidate, ARG-007, effectively reduces axonal injury and neuroinflammation in cases of moderate traumatic brain injury (TBI) in rats. These results suggest that ARG-007 could play a crucial role in preventing the acute and chronic consequences of TBI, potentially positioning the company as a leader in TBI therapeutic interventions.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics to mitigate brain tissue death following strokes, brain injuries, and neurodegenerative diseases. Their lead candidate, ARG-007, is a neuroprotective peptide that has shown promise in preclinical models for stroke, traumatic brain injury (TBI), and hypoxic ischaemic encephalopathy (HIE). The company is currently engaged in Phase 2 clinical trials for acute ischaemic stroke patients.
YTD Price Performance: 11.11%
Average Trading Volume: 113,059
Technical Sentiment Consensus Rating: Sell
Learn more about AGN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue